Massachusetts is currently home to 3150 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparison of Uncomplicated Candidemia Therapy Duration in Children
NCT05763251
Recruiting
The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: * Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. * Compare the 14-day desirability of outcome measure for subjects with a negative and those... Read More
Gender:
ALL
Ages:
Between 120 days and 18 years
Trial Updated:
09/24/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Invasive Candidiasis
Register for Updates
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
NCT05721248
Recruiting
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Dana-Farber Cancer Insitute, Boston, Massachusetts
Conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Modulating Exercise Dosage to Improve Concussion Recovery
NCT05434130
Recruiting
Aerobic exercise has emerged as an effective treatment to reduce sport-related concussion symptom severity, yet existing work lacks rigor regarding the precise exercise volume and intensity required to elicit therapeutic effects, how exercise can alter concussion-related pathophysiology, and whether exercise can prevent the development of secondary sequelae. Our objective is to examine if a high dose exercise program (higher volume than currently prescribed at an individualized, safe intensity l... Read More
Gender:
ALL
Ages:
Between 13 years and 18 years
Trial Updated:
09/24/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Concussion, Brain, Treatment, Aerobic Exercise, Inflammation, Depression, Anxiety
Register for Updates
Gamma-Induction in FrontoTemporal Dementia Trial
NCT04425148
Recruiting
This is an interventional, sham controlled, double-blind study designed to investigate the safety, tolerability and efficacy of 40 Hz transcranial alternating current stimulation (tACS), a form of noninvasive brain stimulation, delivered for 6 weeks once daily in frontotemporal dementia (FTD) patients. Cognition, gamma EEG activity and brain metabolism via FDG-PET will be measured before and after the tACS intervention.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
09/24/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Frontotemporal Dementia
Register for Updates
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
NCT03827694
Recruiting
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
Gender:
ALL
Ages:
Between 120 days and 21 years
Trial Updated:
09/24/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Pulmonary Invasive Aspergillosis, Pulmonary Invasive Fungal Infections
Register for Updates
The COMA Family Program: a Skills-Based Resiliency Program for Caregivers of Patients with Severe Acute Brain Injuries
NCT05761925
Recruiting
The purpose of this study is to pilot a psychosocial skills-based intervention for caregivers of patients with severe acute brain injuries. The data the investigators gather in this study will be used to further refine our COMA-F intervention.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Massachusetts General Hopsital, Boston, Massachusetts
Conditions: Coma, Emotional Distress
Register for Updates
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
NCT05669833
Recruiting
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/23/2024
Locations: University of Massachusetts Chan Medical School, Worcester, Massachusetts
Conditions: Psoriatic Arthritis
Register for Updates
Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT04553770
Recruiting
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Register for Updates
Randomized Controlled Trial for Ankle Fracture Pain Control
NCT03696199
Recruiting
This project is a multicenter, three armed, prospective randomized control trial studying the effectiveness of a long-acting local anesthetic "cocktail" in patients undergoing operative fixation of ankle fractures.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
09/23/2024
Locations: Lahey Hospital & Medical Center, Burlington, Massachusetts
Conditions: Ankle Fractures
Register for Updates
Allogeneic Valve Transplantation
NCT06387446
Recruiting
Valves will be taken from hearts donated by organ donors, and implanted into patients who need a new heart valve.
Gender:
ALL
Ages:
Between 30 days and 50 years
Trial Updated:
09/22/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Valve Heart Disease, Valve Disease, Heart, Valve Disease, Aortic
Register for Updates
Ziftomenib Maintenance Post Allo-HCT
NCT06440135
Recruiting
The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets and inhibits negative interactions within cancer cells related to AML, when given after allo-HCT, to determine if it improves outcomes following allo-HCT. The name of the study drug involved in this s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/20/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, NPM1 Mutation, KMT2A Rearrangement
Register for Updates
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT05362773
Recruiting
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic (affect of the drug on the body), immunogenicity (development of antibodies against the drug), and preliminary anti-cancer effect of MGD024. Par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/20/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia
Register for Updates